References
- Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Am J Obstet Gynecol 2002;187:116–26
- Diokno AC. Epidemiology and psychosocial aspects of incontinence. Urol Clin North Am 1995;22:481–5
- Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. Br J Urol Int 2001;87:760–6
- Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327–36
- Coyne KS, Payne C, Bhattacharyya SK, et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health 2004;7:455–63
- Liberman JN, Hunt TL, Stewart WF, et al. Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey. Urology 2001;57:1044–50
- Hu TW, Wagner TH, Bentkover JD, et al. Estimated economic costs of overactive bladder in the United States. Urology 2003;61:1123–8
- Ouslander JG. Management of overactive bladder. New Engl J Med 2004;350:786–99
- Cardozo L, Lisec M, Millard R, et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004;172(5 Pt 1):1919–24
- Chapple CR, Rechberger T, Al-Shukri S, et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. Br J Urol Int 2004;93:303–10
- Chapple CR, Arano P, Bosch JL, et al. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. Br J Urol Int 2004; 93:71–7
- Sussman D, Garely A. Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the anti-muscarinic clinical effectiveness trial (ACET). Curr Med Res Opin 2002;18:177–84
- Preik M, Albrecht D, O’Connell M, et al. Effect of controlled-release delivery on the pharmacokinetics of oxybutynin at different dosages: severity-dependent treatment of the overactive bladder. Br J Urol Int 2004;94:821–7
- Landis JR, Kaplan S, Swift S, et al. Efficacy of antimuscarinic therapy for overactive bladder with varying degrees of incontinence severity. J Urol 2004;171(2 Pt 1):752–6
- Data on file. Yamanouchi Pharmaceutical Co., Ltd
- van Elteren PH. On the combination of independent two-sample tests of Wilcoxon. Bull Int Stat Inst 1960;37:351–61
- Chapple C, Cardozo L, Steers WD, et al. Solifenacin effectively improves all key symptoms of overactive bladder syndrome. Curr Med Res Opin 2005 [submitted for publication]
- Cardozo L, Castro-Diaz D, Gittelman M, et al. Reductions in overactive bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with solifenacin. Int Urogynecol J Pelvic Floor Dysfunct 2005 [submitted for publication]